Enhanced collaboration with Toshiba strengthens Elekta’s position in Japan

        Print
| Source: Elekta AB
TOKYO, September 1, 2014 – In an agreement signed today in Tokyo, Elekta Japan
will grant Toshiba Medical Systems Corporation (TMSC) wider distribution rights
regarding linear accelerator (linac) sales. The agreement builds on a sales and
marketing agreement from 2010 (http://www.elekta.com/press/44337b95-6e69-4e41
-926d-aaa6d6dbf002/elekta-signs-sales-and-marketing-agreement-with-toshiba-in
-japan-.html).
Shuichi Higaki, President and Managing Director, Elekta Japan, says: “The
existing partnership between Elekta and TMSC from 2010 has helped raise Elekta’s
profile in the Japanese market. This new agreement creates significant
opportunities for Elekta to further increase our customer satisfaction and
become the leading supplier of oncology systems and related software solutions
in Japan.”

Since Siemens’s departure from the linac market in 2011, TMSC still has an
installed base of about 200 aging Siemens linear accelerators. The extended
partnership opens up additional sales channels for Elekta’s linacs and software
products and gives Elekta the opportunity to convert existing Siemens LANTIS
Oncology Information Systems that were sold through TMSC.

The agreement also includes the intention to develop the Elekta Support Center,
a centralized customer support center with a single point of contact for all
Elekta linac users in Japan. Elekta will continue to manage marketing and
promotion of all Elekta products and solutions, as well as education and
training and software service support.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on September 1, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.